S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)

Leisure Travelers May Have Moved Marriott Stock as High as it Can Go

Saturday, November 6, 2021 | Chris Markoch
Leisure Travelers May Have Moved Marriott Stock as High as it Can Go

Marriott Stock Should Stay on Your Watchlist For Now 

After delivering a strong earnings report, shares of Marriott International (NASDAQ: MARare trading above its 52-week high. The relative strength index (RSI) suggests that the rally in MAR stock may be ready to reverse.  

And that bearish sentiment is being echoed by the 13 analysts tracked by MarketBeat. The stock is trading about 13% above the consensus target. However, there are two sides to a story. And in the two days, since the company reported earnings, Marriott has received two price target increases. And although both of those analysts keep MAR stock below its current price, investors should pay close attention to see if further upgrades are in the offing.  

This is creating an interesting dynamic for investors. On the one hand, the stock looks overvalued; on the other hand, technical indicators point to the stock going higher.  

The Comps Will Start to Get Harder 

The company reported earnings that were in line with analysts’ expectations for 99 cents per share. And revenue came in at a better-than-expected $3.95 million as opposed to expectations for $3.71 million.  

Obviously, those numbers are significantly better than the numbers reported in the same quarter in 2020. It’s also obvious that the results are not as good as the numbers Marriott posted in 2019.  

That’s where things get interesting for MAR stock. We’re approximately one year since the announcement that the Covid-19 vaccine from Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) received emergency use authorization. Almost on command, MAR stock began to recover its pandemic losses. But that recovery was stalled first because of the uneven recovery and second due to the emergence of the Delta variant.  


With that in mind, this may be the last quarter in which Marriott is dealing with a low bar to jump over. Now it will be imperative for the company to continue to show that revenue and earnings are moving closer to pre-pandemic levels. 

What Will the New Normal Look LIke? 

I’ve had several occasions to stay in hotels (including full disclosure in some Marriott properties) in the last six months. The words new normal are very apt. There are still many concessions being made to the pandemic. One of the most notable is the current housekeeping situation which remains something that guests should not expect for a multi-day stay. 

In two cases, the hotels I was staying at were benefiting from wedding traffic. And that gave the hotel a somewhat “normal” feel. On a couple of other occasions, it was obvious that it will be awhile before occupancy levels are back to normal. Some of that may resolve itself if, and when, business travel resumes. But nobody can accurately forecast what business travel will look like, particularly with the issue of vaccine mandates hanging in the air.  

However, Marriott did say that special corporate bookings are down less than 40% year-over-year.  

Leisure Travel is Boosting the Stock  

On that note, on the company’s most recent earnings call, Marriott made it clear that the increase in leisure travel was offsetting any concerns about the Delta variant. And Marriott added 17,456 rooms worldwide to accommodate that travel. 

And here’s an interesting aside. The pandemic blurred the lines between business and leisure travel. Many individuals managed to continue working even while engaging in leisure travel. Based on the news coming from many companies, this situation may repeat itself throughout 2022 and perhaps beyond.  

Is MAR Stock a Buy? 

As I pointed out in the opening, something has to give with Marriott stock. I was bullish on Marriott as a recovery stock, because I believe the company is a best-of-breed among hotel stocks. However, at this time, I’d like to see more before buying MAR stock. 

Should you invest $1,000 in Marriott International right now?

Before you consider Marriott International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Marriott International wasn't on the list.

While Marriott International currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Marriott International (MAR)
2.5281 of 5 stars
$162.33-2.4%N/A35.99Hold$181.44
Pfizer (PFE)
2.9905 of 5 stars
$50.67+1.5%3.16%11.62Hold$57.32
BioNTech (BNTX)
1.736 of 5 stars
$151.20-4.8%N/A2.63Hold$260.53
Compare These Stocks  Add These Stocks to My Watchlist 

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.